tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Kontafarma China Approves Major R&D Construction Contract

Story Highlights
Kontafarma China Approves Major R&D Construction Contract

Meet Your ETF AI Analyst

The latest update is out from Kontafarma China Holdings Ltd ( (HK:1312) ).

Kontafarma China Holdings Ltd announced that its adjourned extraordinary general meeting successfully passed all proposed resolutions, including the approval of a significant construction contract for a research and development complex in Beijing. This contract, valued at over RMB33 million, is expected to enhance the company’s R&D capabilities, potentially strengthening its market position and benefiting stakeholders.

More about Kontafarma China Holdings Ltd

Kontafarma China Holdings Ltd is a company involved in the pharmaceutical industry, primarily focusing on research and development projects through its subsidiary, Tongfang Pharmaceutical.

Average Trading Volume: 5,871,050

Technical Sentiment Signal: Sell

Current Market Cap: HK$150.6M

Learn more about 1312 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1